Related Experiment Videos
Integrating services for schizophrenia and substance abuse
D J Hellerstein1, R N Rosenthal, C R Miner
1New York State Psychiatric Institute, Department of Psychiatry, Beth Israel Medical Center, New York, New York, USA. hellers@pi.cpmc.columbia.edu
The Psychiatric Quarterly
|August 30, 2001
Summary
Integrated treatment for schizophrenia and substance use disorders shows promise for patient retention. This approach may improve outcomes for individuals with comorbid conditions, despite previous reviews finding no clear superiority.
Area of Science:
- Psychiatry
- Addiction Medicine
- Clinical Psychology
Background:
- Comorbid schizophrenia and substance use disorders present treatment challenges.
- Previous reviews found no clear evidence for integrated treatment superiority.
- The Combined Psychiatric and Addictive Disorders (COPAD) program offers an integrated approach.
Purpose of the Study:
- To describe the COPAD integrated treatment program.
- To summarize findings from outcome and replication studies.
- To discuss clinical and research issues for this patient population.
Main Methods:
- Description of the COPAD integrated treatment model.
- Summary of findings from initial and replication outcome studies.
- Analysis of clinical and research considerations.
Main Results:
- Data suggests benefits of integrated treatment for patients with addictive disorders and schizophrenia.
- Treatment retention was notably improved with the integrated approach.
- Key clinical issues include risk identification, assessment, treatment planning, and engagement.
Conclusions:
- Integrated treatment, as exemplified by the COPAD program, shows potential benefits for patients with comorbid schizophrenia and substance use disorders.
- Improved treatment retention is a significant finding supporting integrated care.
- Addressing clinical complexities like patient engagement is crucial for successful outcomes.